Gernon Longo, MD
Vascular Surgery · Omaha, NENPI 1376593707
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $231 of the $333 with a category attached, or 69.4%. 4 manufacturers reported payments, led by Silk Road Medical, Inc. at 50.6% of the total. Reporting peaked in 2019 at $275 and has fallen 93.1% since, to $19 in 2023. That places this record below the midpoint for vascular surgery clinicians in NE, where the typical reported total is $4,193.
Across 7 payments — averaging $47.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Silk Road Medical, Inc.$169
- W. L. Gore & Associates, Inc.$77
- Bolton Medical Inc$72
- Medtronic$15
Across 15 payments — averaging $1499.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Surmodics, Inc.$12K
- W. L. Gore & Associates, Inc.$11K
What the payments were for
- Travel & lodging$10231%
- Food & beverage$23169%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Silk Road Medical, Inc. | 2 | $169 |
| W. L. Gore & Associates, Inc. | 3 | $77 |
| Bolton Medical Inc | 1 | $72 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$333 in reported general payments places this provider in the 30th percentile of 35 vascular surgery providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 11 | $9,525 |
| EliquisApixaban | 12 | $6,557 |
| Cilostazol | 46 | $1,147 |
| ClopidogrelClopidogrel Bisulfate | 99 | $840 |
| Atorvastatin Calcium | 63 | $425 |
| Rosuvastatin Calcium | 31 | $101 |
| Gabapentin | 23 | $77 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Omaha
- John ParkOmaha$508K
- David VogelOmaha$41K
- Marcus BaltersOmaha$27K
- Anjan TalukdarOmaha$25K
- Iraklis PipinosOmaha$24K
- Rao GuttaOmaha$21K
- Tammy RamosOmaha$10K
- Yue GaoOmaha$9K
- Jason CookOmaha$7K
- Katherine BrownOmaha$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.